Balboa Wealth Partners Sells 1,072 Shares of Pfizer Inc. $PFE

Balboa Wealth Partners lessened its position in Pfizer Inc. (NYSE:PFE) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,672 shares of the biopharmaceutical company’s stock after selling 1,072 shares during the period. Balboa Wealth Partners’ holdings in Pfizer were worth $719,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Advisory Group Advisory Services LLC lifted its holdings in shares of Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares in the last quarter. Citizens National Bank Trust Department raised its position in Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 395 shares during the last quarter. Trust Co of the South lifted its stake in Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after acquiring an additional 441 shares during the period. Charter Oak Capital Management LLC boosted its holdings in shares of Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 444 shares during the last quarter. Finally, Ballentine Partners LLC grew its stake in shares of Pfizer by 0.5% in the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after acquiring an additional 458 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Price Performance

NYSE PFE opened at $24.52 on Monday. The business’s fifty day moving average is $24.89 and its 200 day moving average is $24.11. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $139.38 billion, a PE ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.